Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P32

ECE2006 Poster Presentations Bone (46 abstracts)

Baseline characteristics of postmenopausal Greek women with osteoporosis who had inadequate clinical response to antiresorptive medications.

A Ginis 1 , E Charalampidou 1 , N Thalassinos 2 & the Hellenic OSSO Study Group 2


1Medical department of Clinical Research, Pharmaserve-Lilly SACI, Athens, Greece; 2Diabetes and Metabolism Department, General Hospital Evangelismos, Athens, Greece.


Aims: The Observational Study of Severe Osteoporosis (OSSO) is a 12-month, European, prospective study aiming to assess the changes in Health Related Quality of Life (HRQoL) of women with osteoporosis (OP) and an inadequate clinical response to antiresorptive (AR) medications.

Methods: In Greece, 263 of 271 (97%) patients (pts) with severe OP met the inclusion criteria. The study population was assigned to1of 2 groups according to one or more of the following criteria: a) Pts who sustained a new clinical fragility fracture, despite an AR treatment at least 12 months prior to this fracture (Group A); b) Pts who discontinued AR therapy because of non compliance and/or side effects (Group B). After applying a Bonferroni correction, p-values less than 0.003 were considered statistically significant.

Results: Group A consisted of 143 pts (54.4%) aged 71.4 yrs with BMI 27.4 kg/m2. T-score was −3.1 both at the lumbar spine vertebra (LSV) and femoral neck (FN). Group B consisted of 120 pts (45.6%) with aged 64.7 yrs and BMI of 26.4 with T-score −3.1 at LSV and −2.6 at FN. 63% and 42% from groups A and B respectively had ≥1 fragility fractures (excluding the index fracture that made them eligible for the study) <40 yrs. In group A calcitonin (CAL) was the most common OP treatment taken at study entry (47.6%) followed by bisphosphonates (BPs) (39.2%=Aln+Ris+Eti+Pam=(34+16+5+1)/143) while for group B BPs was 40.8% and CAL was 15.0%. Alendronate was the most frequently discontinued qualifying AR drug (38.2%) due to non compliance. The 2 groups were similar with respect to age at menopause (46.5 yrs), number of live born children, hearing (19.8%) and sight problems (49.0%). Differences were observed between groups A and B in yrs past menopause (25.0 vs 17.9), current (18.9% vs 7.5%) and past (25.9% vs 11.7%) use of glucocorticoids and women who had falls in previous year (51.1% vs 31.7%).

Conclusions: Despite the differences observed in baseline characteristics between the 2 groups of postmenopausal women with inadequate response to AR therapy according to the previously mentioned criteria they both had numerous risk factors for a next fracture.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.